The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

Autor: Agoston Gyula Szabo, Jonathan Thorsen, Katrine Fladeland Iversen, Mette Bøegh Levring, Carsten Helleberg, Emil Hermansen, Søren Thorgaard Bønløkke, Katrine Nielsen, Elena Manuela Teodorescu, Eva Kurt, Casper Nørgaard Strandholdt, Annette Juul Vangsted

Publikováno v: eJHaem, Vol 4, Iss 4, Pp 1006-1012 (2023)

Abstract Pomalidomide‐dexamethasone (Pd) has been a standard care treatment for relapsed and refractory multiple myeloma since 2013. However, the outcomes of Pd after exposure to CD38 antibodies are not known. Here we describe the real‐world use

Externí odkaz: https://doaj.org/article/ce92d554cd744369a62207a6600f37a8

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio

Autor: Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Niels Abildgaard, Henrik Gregersen, Trine Silkjær, Per Trøllund Pedersen, Robert Schou Pedersen, Carsten Helleberg, Emil Hermansen, Brian Iversen Schnack, Annette Juul Vangsted

Publikováno v: Blood Cancer Journal, Vol 11, Iss 4, Pp 1-4 (2021)

Externí odkaz: https://doaj.org/article/eb61fd34fa684d79b0312668fd4bd0bc

Geographical and ecological analyses of multiple myeloma in Denmark:Identification of potential hotspot areas and impact of urbanisation

Autor: Lise Dueholm Bertelsen, Lars Børty Nielsen, Heidi Søgaard Christensen, Martin Bøgsted, Henrik Gregersen, Robert Schou Pedersen, Anja Klostergaard, Brian Iversen Schnack, Per Trøllund Pedersen, Niels Abildgaard, Emil Hermansen, Annette Juul Vangsted, Marianne Tang Severinsen

Publikováno v: Bertelsen, L D, Børty Nielsen, L, Christensen, H S, Bøgsted, M, Gregersen, H, Pedersen, R S, Klostergaard, A, Schnack, B I, Pedersen, P T, Abildgaard, N, Hermansen, E, Vangsted, A J & Severinsen, M T 2023, ' Geographical and ecological analyses of multiple myeloma in Denmark : Identification of potential hotspot areas and impact of urbanisation ', European Journal of Haematology, vol. 110, no. 3, pp. 289-295 . https://doi.org/10.1111/ejh.13904

BACKGROUND: The aetiology of multiple myeloma (MM) is unknown but various environmental exposures are suspected as risk factors. We present the first paper analysing the geographical distribution of MM in Denmark at the municipal level to investigate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb092556b1e6a9e44411702ce3f9f339
https://vbn.aau.dk/ws/files/539419718/European_J_of_Haematology_-_2022_-_Bertelsen_-_Geographical_and_ecological_analyses_of_multiple_myeloma_in_Denmark_.pdf

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy

Autor: Annette Juul Vangsted, Manuela Teodorescu, Birgitte Preiss, Mette Bøegh Levring, Jonathan Thorsen, Agoston Gyula Szabo, Eva Kurt, Lise Mette Rahbek Gjerdrum, Carsten Helleberg, Marie Fredslund Breinholt, Katrine Nielsen, Marveh Dokhi, Katrine Fladeland Iversen, Mette K. Andersen, Emil Hermansen, Eigil Kjeldsen, Søren Bønløkke, Casper Strandholdt

Publikováno v: Szabo, A G, Thorsen, J, Iversen, K F, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S T, Nielsen, K, Kjeldsen, E, Teodorescu, E M, Dokhi, M, Kurt, E, Strandholdt, C N, Andersen, M K & Vangsted, A J 2022, ' The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy ', American Journal of Hematology, vol. 97, no. 3, pp. E117-E120 . https://doi.org/10.1002/ajh.26449
Szabo, A G, Thorsen, J, Iversen, K F, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Gjerdrum, L M R, Bønløkke, S, Nielsen, K, Kjeldsen, E, Teodorescu, M, Dokhi, M, Kurt, E, Strandholdt, C N, Andersen, M K & Vangsted, A J 2021, ' The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy ', Blood, vol. 138, no. Suppl. 1, 3779 . https://doi.org/10.1182/blood-2021-152070

Daratumumab is an integral part of the treatment of multiple myeloma (MM) but its real-world efficacy has only been described in small cohorts. MAMMOTH is the only large multi-center study that reported the outcomes of CD38-refractory MM. The present

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::297707d8db084b25ae8fb54726820d26
https://portal.findresearcher.sdu.dk/da/publications/035148e8-81ab-4df0-9c3e-3f92d4c8d59e

Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study

Autor: Maria-Victoria Mateos, Paula Rodriguez Otero, Youngil Koh, Joaquin Martinez-Lopez, Gurdeep Parmar, H. Miles Prince, Hang Quach, Paz Ribas, Emil Hermansen, Vania T.M. Hungria, Sevgi Kalayoglu Besisik, Jin Seok Kim, Xavier Leleu, Valdas Pečeliūnas, Fredrik Schjesvold, Omur G. Sevindik, Tatiana Lavrova, Franck Dubin, Christine Devisme, Lucie Lepine, Sandrine Macé, Mony Morisse, Irene Ghobrial

Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients (pts) with high-risk smolde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a625388b7e086ccf704fd1a7a005cf9
https://hdl.handle.net/20.500.12511/10630